Letter to the Editor: ¹H, ¹³C, and ¹⁵N resonance assignment of the vascular endothelial growth factor receptor-binding domain in complex with a receptor-blocking peptide

Borlan Pan & Wayne J. Fairbrother*

Department of Protein Engineering, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, U.S.A.

Received 25 October 2001; Accepted 26 November 2001

Key words: angiogenesis, NMR resonance assignment, vascular endothelial growth factor

Biological context

Vascular endothelial growth factor (VEGF) is a homodimeric member of the cystine-knot family of growth factors (Muller et al., 1997) that functions as an endothelial cell-specific mitogen and is a primary modulator of physiological angiogenesis (Ferrara, 2001). VEGF is also an important mediator of pathological angiogenesis in a variety of disorders including cancer, proliferative retinopathies, rheumatoid arthritis, age-related macular degeneration, and psoriasis (Folkman, 1995); antagonists of VEGF therefore have therapeutic potential. Six different isoforms of VEGF share a common N-terminal receptor-binding domain of 115-residues/monomer. VEGF functions by binding to and dimerizing its tyrosine kinase receptors, KDR and Flt-1, using a pair of identical binding sites localized at the poles of the dimeric receptor-binding domain.

Three classes of disulfide-constrained peptides that block binding of VEGF to its receptors were identified recently using phage-display methods (Fairbrother et al., 1998). Characterizing the interaction between the peptide antagonists and the VEGF receptorbinding domain could lead potentially to the design of novel, small-molecule antagonists of VEGF. A crystal structure of one of the peptide antagonists in complex with VEGF₈₋₁₀₉ revealed it to be a poor candidate for epitope transfer to a small-molecule scaffold (Wiesmann et al., 1998). Unfortunately, the highest-affinity class of peptides has not proved amenable to crystallographic analysis. As a first step in characterizing the complex between VEGF and this class of phagederived peptide antagonists by NMR, we report here nearly complete assignments for VEGF₁₁₋₁₀₉ in complex with peptide v107. Comparison with backbone assignments reported previously for free VEGF₁₁₋₁₀₉ (Fairbrother et al., 1997) allows for identification of the peptide-binding site via quantitative chemical shift mapping.

Methods and experiments

The receptor-binding domain of human VEGF (VEGF₁₁₋₁₀₉) was overexpressed in *Escherichia coli* as a His-tagged protein, purified, refolded and cleaved specifically as described previously (Fairbrother et al., 1997). Samples of the VEGF/v107 complex for NMR studies contained 1.0 mM 13 C/ 15 N-labeled VEGF₁₁₋₁₀₉ dimer and 2.25 mM synthetic v107 in 0.5 ml of 50 mM NaCl, 20 mM NaH₂PO₄ (pH 7.0), 0.002% sodium azide, and either 90% H₂O/10% D₂O or 100% D₂O, as appropriate.

Spectra were acquired at 45 °C on either a Bruker DRX-600 or DRX-800 spectrometer equipped with 5-mm inverse triple-resonance probes with three-axis gradient coils. Backbone ${}^{1}\text{H}^{N}$, ${}^{13}\text{C}$, and ${}^{15}\text{N}$ resonances were assigned sequentially using the following experiments (Cavanagh et al., 1995): 2D ${}^{15}\text{N}$ -HSQC, and ${}^{13}\text{C}$ -HSQC, and 3D HNCO, (HCA)CONH, HNCA, and CBCA(CO)NH. The backbone resonance assignments were verified by observation of sequential correlations in a 3D ${}^{15}\text{N}$ -edited NOESY-HSQC spectrum (mixing time, 80 ms). Aliphatic side-chain resonance assignments were obtained from analysis of 3D HBHA(CO)NH, HCC(CO)NH, and HCCH-TOCSY spectra. Aromatic resonance assignments were obtained from a 3D ${}^{13}\text{C}$ -edited NOESY-HSQC spectrum

^{*}To whom correspondence should be addressed. E-mail: fairbro@gene.com



Figure 1. (a) Plot of weighted net change in VEGF₁₁₋₁₀₉ chemical shifts for ¹H^N, ¹³C', and ¹⁵N resonances of free and v107-bound protein. (b) Mapping of the quantitative chemical shift perturbations on the crystal structure of VEGF. Red colors indicate greater chemical shift perturbations.

(mixing time, 110 ms) centered in the aromatic region. Assignments for the Asn and Gln side-chain amide groups were determined from the ¹⁵N-edited NOESY-HSQC spectrum. Stereospecific assignments of β -methylenes were determined by analysis of HNHB, ¹³C-edited NOESY-HSQC, and ¹⁵N-edited NOESY-HSQC spectra. Spectra were processed using FE-LIX (Accelrys, Inc.) and analyzed using FELIX and XEASY (Bartels et al., 1995).

Extent of assignments and data deposition

Backbone assignments for VEGF₁₁₋₁₀₉ in complex with v107 are essentially complete, except for ¹⁵N of all 7 prolines, ¹⁵N, ¹H^N, and ¹³C' of the two N-terminal residues, H11 and H12, and ¹⁵N, and ¹H^N of E13 and N62. All expected intraresidue and sequential ¹³C^{α} and ¹³C' correlations were observed (where expectation is based on the observed amide resonances). The side-chain assignments are also complete except for ¹H⁸²/¹³C⁸² and ¹H^{ε1}/¹³C^{ε1} of histidines and ¹H^ε/¹⁵N^ε of arginines. Stereospecific assignments were established for 17 of 52 βmethylenes having nondegenerate proton resonances. The ¹H, ¹³C, and ¹⁵N resonance assignments have been deposited in the BioMagResBank (BMRB; http://www.bmrb.wisc.edu) under accession number 5185.

Broadening of the backbone amide resonances of N62 in the VEGF/v107 complex is consistent with similar broadening observed for C61, N62, E64, and G65 in spectra of free VEGF $_{11-109}$ (Fairbrother et al., 1997), and suggests conformational averaging in this region. Note that new high-field data have lead to revision of some tentative assignments reported for free VEGF $_{11-109}$; the revised backbone assignments have been deposited also in the BMRB under accession number 5186. V107-induced chemical shift perturbations of VEGF₁₁₋₁₀₉ were assessed quantitatively; the weighted net change in $VEGF_{11-109}$ chemical shifts for backbone ¹H^N, ¹³C', and ¹⁵N resonances (Meininger et al., 2000) of free and v107bound $VEGF_{11-109}$ are plotted in Figure 1a. The chemical shift perturbations are localized to the pole regions of the VEGF dimer (Figure 1b), corresponding closely to the previously determined binding sites for the VEGF receptors KDR and Flt-1 (Muller et al., 1997; Wiesmann et al., 1997).

Acknowledgements

We thank Nicholas Skelton and Melissa Starovasnik for discussions and assistance, Jeffrey Tom for peptide synthesis, and James Bourell for mass spectrometry support.

References

- Bartels, C., Xia, T., Billeter, M., Guntert, P. and Wüthrich, K. (1995) *J. Biomol. NMR*, **6**, 1–10.
- Cavanagh, J., Fairbrother, W.J., Palmer, III, A.G. and Skelton, N.J. (1995) Protein NMR Spectroscopy: Principles and Practice, Academic Press, San Diego.
- Fairbrother, W.J., Champe, M.A., Christinger, H.W., Keyt, B.A. and Starovasnik, M.A. (1997) Protein Sci., 6, 2250–2260.
- Fairbrother, W.J., Christinger, H.W., Cochran, A.G., Fuh, G., Keenan, C.J., Quan, C., Shriver, S.K., Tom, J.Y.K., Wells, J.A. and Cunningham, B.C. (1998) *Biochemistry*, 37, 17754–17764.
- Ferrara, N. (2001) Am. J. Physiol. Cell Physiol., 280, C1358-C1366.
- Folkman, J. (1995) Nat. Med., 1, 27-31.
- Meininger, D.P., Rance, M., Starovasnik, M.A., Fairbrother, W.J. and Skelton, N.J. (2000) *Biochemistry*, **39**, 26–36.
- Muller, Y.A., Li, B., Christinger, H.W., Wells, J.A., Cunningham, B.C. and de Vos, A.M. (1997) *Proc. Natl. Acad. Sci. USA*, 94, 7192–7197.
- Wiesmann, C., Christinger, H.W., Cochran, A.G., Cunningham, B.C., Fairbrother, W.J., Keenan, C.J., Meng, G. and de Vos, A.M. (1998) *Biochemistry*, 37, 17765–17772.
- Wiesmann, C., Fuh, G., Christinger, H.W., Eigenbrot, C., Wells, J.A. and de Vos, A.M. (1997) *Cell*, **91**, 695–704.